Trial Profile

A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bivalent influenza modRNA vaccine-Pfizer (Primary) ; BNT 161 (Primary) ; Monovalent influenza modRNA vaccine-Pfizer (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

03 Mar 2023 Status changed from recruiting to completed.
18 Oct 2022 Planned number of patients changed from 615 to 1980.
08 Sep 2022 Planned number of patients changed from 1980 to 615.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com